Houston-based March Biosciences, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children’s Hospital), is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in a Phase 2 trial for patients with relapsed and refractory T cell lymphoma, a disease with extremely limited treatment options and a dismal prognosis. The Phase 2 trial builds off of a successful Phase 1 study conducted by BCM which demonstrated favorable safety data and the potential to induce long term remissions. March is founded alongside the inventing scientists Dr. Maksim Mamonkin and Dr. Malcolm Brenner and serial entrepreneur Dr. Sarah Hein. The company has raised over $52 million to date, inclusive of venture financing, support from the Cancer Prevention & Research Institute of Texas (CPRIT), and the NIH SBIR program. Fitz Gate participated in March Bio’s oversubscribed Series A round.
